Veamos si hoy Mottley Fool con este comentario y rumot dr BO, anima al retalil a comprar mas y nos calienta la accion y nos aleja del rojo vino que nos tienen anunciado los futuros para hoy
-- ----
Novavax shined in January, but February may be even better for this small-cap biotech stock.
George Budwell
(
TMFGBudwell)
Feb 4, 2018 at 4:49PM
What happened
The catalyst? The biotech's shares are apparently
benefiting from the news that the current cohort of FDA-approved flu vaccines from GlaxoSmithKline (
NYSE:GSK) and Sanofi (
NYSE:SNY) have largely failed to curtail the ongoing epidemic. The Centers for Disease Control, after all, recently deemed this season to be one of the most severe, and deadly, in over a decade.
So what
Novavax is on track to release early-stage data for its flu vaccine candidate, NanoFlu, this month. These preliminary data are unlikely to be enough to warrant an accelerated approval from regulators, but they may spark a buyout offer from the current market share leaders Glaxo and Sanofi.
As such, Sanofi and Glaxo appear to be logical suitors for Novavax in the event that NanoFlu proves to be efficacious and safe in human beings.
https://www.fool.com/investing/2018/02/04/why-novavax-inc-stock-blasted-off-in-january.aspx